Clinical Review Criteria — Radiopharmaceuticals (Lutathera and Pluvicto)
Customize your policy alerts
Sign up for all Kaiser Permanente policy alerts
Know when Kaiser Permanente releases new policies or updates existing guidance.
Monitor payer policy activity
Clinical review criteria governing medical necessity determinations for Lutathium Lu 177 dotatate (Lutathera) for somatostatin receptor‑positive GEP‑NETs and Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for metastatic castration‑resistant prostate cancer, for use by Kaiser Foundation Health Plan of Washington providers and members.
MPC approved to adopt hybrid medical necessity criteria for Lutetium Lu 177 vipivotide tetraxetan (Pluvicto); effective 12/01/2026.
Updated radiologic response language with parentheticals to clarify intent under renewal criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.